138
Development of a dual-modally traceable nanoplatform for
cancer theranostics using natural circulating microparticles
in oral cancer patients
Z.L. Yu
∗
, W. Zhang, Y.F. Zhao
Department of Oral and Maxillofacial Surgery, School and
Hospital of Stomatology, Wuhan University, Wuhan, China
Background:
Circulating microparticles (CMPs), which are
nano-sized (100–1000 nm) membrane vesicles shed into circula-
tion by various cell types, have been recently recognised as natural
conveyors of molecular information and exhibit great potential to
serve as therapeutic platforms.
Objectives:
The present study aims to transform the CMPs into
multifunctional therapeutic nanovectors.
Methods:
CMPs, which were freshly purified from the periph-
eral blood of oral squamous cell carcinoma (OSCC) patients,
were embeddedwith ultrasmall near infrared-fluorescent magnetic
quantum dots (Ag2Se@Mn QDs) via electroporation. The tissue
distribution and natural tumour-targeting behaviour of CMPs were
evaluated in living mice with
in vivo
magnetic resonance imaging
(MRI) system and 7.0 T small animal MRI scanner. To develop
a dual-modally traceable nanoplatform for cancer theranostics,
siRNA and Ag2Se@Mn QDs were simultaneously loaded into
CMPs via electroporation.
Findings:
CMPs were efficiently labeled with Ag2Se QDs
through electroporation with favourable biocompatibility. Due to
the favourable biocompatibility and superior dual-mode traceabil-
ity of Ag2Se@Mn QD-labeled CMPs, we investigated the
in vivo
biodistribution patterns of CMPs and revealed the excellent natural
tumour-targeting activity of CMPs in living mice. Importantly, the
siRNA/Ag2Se QDs-loaded CMPs exhibited excellent therapeutic
effects in an oral cancer-bearing mouse model.
Conclusions:
This study not only realised the first efficient
labelling and
in vivo
dual-mode tracking of CMPs that were
directly isolated from human body fluids but also transformed
these naturally occurring MPs into multifunctional nanovectors,
opening new avenues for the development of real natural thera-
nostic nanoplatforms.
http://dx.doi.org/10.1016/j.ijom.2017.02.478CXCL12 via recruiting regulatory CD4(+) T cells promote
tumour progression in tumour microenvironment
B. Zhang
∗
, C. Li, L. Li
West China Hospital of Stomatology (Sichuan University),
Chengdu, China
Background:
Signals mediated by CXCL12 (SDF1) and its recep-
tor CXCR4 are centrally involved in cancer progression, both
directly by activating cancer cells and indirectly by inducing
angiogenesis plus recruiting regulatory T cells. FoxP3+ T cells, a
marker for regulatory CD4(+) T cells (Tregs), populate tumours
and regulate antitumour immunity.
Objective:
To explore the antitumour immunity role of SDF1 in
tumour microenvironment, we stained and counted the number of
Tregs in 72 oral squamous cell carcinoma (OSCC) patients via
immunohistochemistry staining of FoxP3+.
Findings and Conclusions:
The results indicated that a positive
correlation between CXCL12 expression levels and Tregs number.
In this series of 72 OSCC patients, the SDF-1 expression level cor-
related significantly with overall survival. Our findings elucidate
a central role for SDF1 recruiting Tregs in tumour microenvi-
ronment promoting tumour progression. The prognostic value of
SDF1 was confirmed by a multivariate analysis.
http://dx.doi.org/10.1016/j.ijom.2017.02.479Overexpression of stathmin 1 leads to docetaxel based
induction chemotherapy resistance via mutant p53 in oral
squamous cell carcinoma
L.P. Zhong
∗
, H.L. Ma, S.F. Jin, Y.Y. Tu, L. Jiang, Z.Y. Zhang
Department of Oral and Maxillofacial-Head and Neck
Oncology, Ninth People’s Hospital, Shanghai Jiao Tong
University School of Medicine, Shanghai, China
Background:
A phase 3 trial (NCT01542931) demonstrated fail-
ure to improve survival when docetaxel, cisplatin, 5-fluorouracil
(TPF) induction chemotherapy was added to standard therapy
compared to standard therapy alone in patients with locally
advanced oral squamous cell carcinoma (OSCC).
Objectives:
To investigate the predictive value of stathmin expres-
sion and its role in tumourigenesis and chemoresistance as well
as its transcriptional regulation by mutant p53 in OSCC.
Methods:
Expression of stathmin was evaluated by immunohisto-
chemistry in pretreatment biopsies from 256 OSCC patients in the
phase 3 trial. Tumourigenicity and chemoresistance regulated by
stathmin was investigated using
in vitro
and
in vivo
OSCCmodels.
Regulation of mutant p53 on stathmin was detected by ChIP and
dual-luciferase reporter assays.
Findings and Conclusion:
OSCC patients with low stath-
min expression benefited from TPF induction chemother-
apy, which was associated with increased overall survival
(
P
= 0.028), disease-free survival (
P
= 0.010), locoregional
recurrence-free survival (
P
= 0.010), and distant metastasis-free
survival (
P
= 0.027). Overexpression of stathmin was identified
and confirmed in OSCC tissues and lines. Downregulation of
stathmin expression in OSCC lines significantly inhibited cell
proliferation, colony formation, migration and tumourigenesis,
and enhanced sensitivity to docetaxel and cisplatin
in vitro
and
in vivo
. Mutant p53 (R175H, G245C, and R282W) bound to
the stathmin promoter and transcriptionally regulated stathmin
expression. These results suggest that low stathmin expression
is a predictive biomarker, identifying those patients with locally
advanced OSCC who may benefit from TPF induction chemother-
apy. Overexpression of stathmin promotes tumour progression and
chemoresistance to docetaxel and cisplatin, and it is transcription-
ally activated by mutant p53 in OSCC.
http://dx.doi.org/10.1016/j.ijom.2017.02.480




